Analysts' Revenue Estimates For Calliditas Therapeutics AB (publ) (STO:CALTX) Are Surging Higher

Celebrations may be in order for Calliditas Therapeutics AB (publ) (STO:CALTX) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects. The market seems to be pricing in some improvement in the business too, with the stock up 7.5% over the past week, closing at kr94.80. Whether the upgrade is enough to drive the stock price higher is yet to be seen, however.

After this upgrade, Calliditas Therapeutics' five analysts are now forecasting revenues of kr625m in 2022. This would be a major 173% improvement in sales compared to the last 12 months. Before the latest update, the analysts were foreseeing kr563m of revenue in 2022. It looks like there's been a clear increase in optimism around Calliditas Therapeutics, given the nice increase in revenue forecasts.

Check out our latest analysis for Calliditas Therapeutics

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Calliditas Therapeutics' past performance and to peers in the same industry. It's clear from the latest estimates that Calliditas Therapeutics' rate of growth is expected to accelerate meaningfully, with the forecast 173% annualised revenue growth to the end of 2022 noticeably faster than its historical growth of 45% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 28% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Calliditas Therapeutics is expected to grow much faster than its industry.

The Bottom Line

The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for this year. Analysts also expect revenues to grow faster than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Calliditas Therapeutics.

That's a pretty serious upgrade, but shareholders might be even more pleased to know that forecasts expect Calliditas Therapeutics to be able to reach break-even within the next few years. You can learn more about these forecasts, for free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.